TEL AVIV, Israel, Dec. 3, 2019 /PRNewswire-PRWeb/ -- MaxQ AI, the industry-leading medical diagnostic AI company, today announced that it has achieved ISO 27001 certification, a widely-recognized international standard outlining standards for information security management systems. With cyberattacks representing a growing threat to healthcare organizations and systems – last year the number of reported data breaches nearly tripled with more than 15 million patient records compromised – there is a growing demand that healthcare technology providers commit to stringent security standards requiring governance and controls(1).
"Although ISO 27001 certification is not mandatory at this time, MaxQ AI chose to pursue this higher standard because we understood the commercial benefits for our channel partners and for the healthcare sector as a whole," said Robert Mehler, Co-Founder, Chief Operating Officer and Chief Information Security Officer for MaxQ AI. "Cybersecurity is a threat that goes far beyond lost revenue and expenses. An attack can have dire, potentially irreparable consequences for patient care and to the healthcare organization's reputation."
To achieve certification, MaxQ AI undertook a year-long process to prepare, which involved the entire company, working closely with the its Quality Management System team (QMS) to ensure close alignment to the company's rigorous quality standards. MaxQ AI's "security-by-design" approach is also paramount in this process as the company works to build security into every part of the IT management and operations process – sales, marketing, finance, and human resources. In addition, MaxQ AI has engaged the company's extensive network of global and trusted CT, PACS, and AI ecosystem partners to collaborate on comprehensive security solutions that ensure data integrity, monitoring, and access rights management.
MaxQ AI has developed the revolutionary ACCIPIO® ICH and Stroke Platform, which integrates into a comprehensive, seamless, and secure workflow to augment acute care teams with deep clinical insight and actionable data in minutes. These AI-powered insights enable physicians across the world to make faster assessments of stroke, traumatic brain injury, and head trauma in any location, at any time. Accipio Ix™ provides automatic identification and prioritization of non-contrast head CT images with suspected ICH. Accipio Ax™ delivers automatic slice-level annotation of suspected ICH. Both Accipio Ix and Ax are FDA Cleared and CE Approved. The Accipio platform is comprised of Class II and Class III medical devices with significant clinical evidence.
About MaxQ AI, Ltd.
MaxQ AI is at the forefront of Medical Diagnostic AI. We are transforming healthcare by empowering physicians to provide "smarter care" with artificial intelligence (AI) clinical insights. Based in Tel Aviv, Israel and Andover, MA, USA, our team of deep learning and machine vision experts develop innovative software that uses AI to interpret medical images and surrounding patient data. Working with world-class clinical and industry partners, our software enables physicians to make faster, more accurate decisions when diagnosing stroke, traumatic brain injury, and other serious conditions. To learn more, visit http://www.maxq.ai or follow us on Twitter and LinkedIn.
###
(1) Source: 2019 Annual Breach Barometer Report; https://www.prnewswire.com/news-releases/breached-patient-records-tripled-in-2018-vs-2017-as-health-data-security-challenges-worsen-300793374.html
SOURCE MaxQ AI
Share this article